Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis

被引：18
|
作者：
Dosanjh, AK [1 ]
Wan, B [1 ]
Throndset, W [1 ]
Sherwood, S [1 ]
Morris, RE [1 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
来源：
TRANSPLANTATION PROCEEDINGS | 1998年 / 30卷 / 05期
关键词：
D O I：
10.1016/S0041-1345(98)00478-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1910 / 1911
页数：2
相关论文
共 50 条
  • [21] The effect of an antifibrotic agent, pirfenidone, on penile erectile function in an experimental rat model of ischemic priapism
    Onder Cinar
    Mustafa S. Bolat
    Salih Erdem
    Esin Kaymaz
    Engin D. Demirkiran
    Reha Girgin
    Ersan Bulut
    Bulent Akduman
    Necmettin A. Mungan
    International Journal of Impotence Research, 2020, 32 : 232 - 238
  • [22] The effect of an antifibrotic agent, pirfenidone, on penile erectile function in an experimental rat model of ischemic priapism
    Cinar, Onder
    Bolat, Mustafa S.
    Erdem, Salih
    Kaymaz, Esin
    Demirkiran, Engin D.
    Girgin, Reha
    Bulut, Ersan
    Akduman, Bulent
    Mungan, Necmettin A.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2020, 32 (02) : 232 - 238
  • [23] Clotrimazole inhibits lung fibroblast proliferation in vitro - Implications for use in the prevention and treatment of obliterative bronchiolitis after lung transplantation
    Smith, MA
    Zhang, WJ
    Naziruddin, B
    Cooper, JD
    Patterson, GA
    Mohanakumar, T
    TRANSPLANTATION, 2000, 70 (08) : 1263 - 1267
  • [24] Effect of pirfenidone, a novel antifibrotic agent, on PDGF- and TGFB1-induced intracellular events in rat hepatic stellate cells.
    Di Sario, A
    Bendia, E
    Saccomanno, S
    Ridolfi, F
    Ugili, L
    Trozzi, T
    Neri, R
    Marzioni, M
    Jezequel, AM
    Benedetti, A
    HEPATOLOGY, 2000, 32 (04) : 188A - 188A
  • [25] Antifibrotic Agent, Pirfenidone, Inhibits Pancreatic Stellate Cells and Tumor-Stromal Interaction in Pancreatic Cancer
    Kozono, S.
    Ohuchida, K.
    Eguchi, D.
    Fujiwara, K.
    Zhao, M.
    Cui, L.
    Mizumoto, K.
    Tanaka, M.
    PANCREAS, 2012, 41 (08) : 1377 - 1377
  • [26] Pirfenidone as a novel cardiac protective treatment
    Alberto Aimo
    Giosafat Spitaleri
    Giorgia Panichella
    Josep Lupón
    Michele Emdin
    Antoni Bayes-Genis
    Heart Failure Reviews, 2022, 27 : 525 - 532
  • [27] Pirfenidone as a novel cardiac protective treatment
    Aimo, Alberto
    Spitaleri, Giosafat
    Panichella, Giorgia
    Lupon, Josep
    Emdin, Michele
    Bayes-Genis, Antoni
    HEART FAILURE REVIEWS, 2022, 27 (02) : 525 - 532
  • [28] Biomarkers of fibrotic interstitial pneumonia with antifibrotic agent treatment
    Maeda, Takashi
    Inomata, Minoru
    Ito, Ken
    Misumi, Akari
    Misumi, Akari
    Chin, Haruka
    Ito, Yu
    Sakamoto, Keita
    Awano, Nobuyasu
    Kuse, Naoyuki
    Izumo, Takehiro
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [29] Pharmacokinetics, tolerability, and safety of pirfenidone (PFD), an antifibrotic agent, following single and multiple oral doses in healthy volunteers
    Shi, Shaojun
    Wu, Jianhong
    Chen, Huating
    Chen, Hui
    Wu, Jun
    Zeng, Fandian
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 197 - 197
  • [30] Antifibrotic Agent Pirfenidone Protects against Development o Radiation-Induced Pulmonary Fibrosis in a Murine Model
    Qin, Wan
    Liu, Bo
    Yi, Minxiao
    Li, Long
    Tang, Yang
    Wu, Bili
    Yuan, Xianglin
    RADIATION RESEARCH, 2018, 190 (04) : 396 - 403
12345